Did you mean sn 101 of nepicastat of ネピキャスタット?
Displaying drugs 326 - 350 of 8238 in total
Daprodustat
Daprodustat is a small-molecule hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor that was developed by GSK.[A254167,A254162] Patients with CKD cannot induce erythropoietin (EPO) production in response to hypoxia or anemia. As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular HIF1α and HIF2α and the induces...
Approved
Investigational
Matched Description: … for non-dialysis patients with anemia of CKD. ... As a potent inhibitor of PHD1, PHD2 and PHD3 (≥ 1000-fold selectivity), daprodustat stabilizes cellular ... [A254172]
In June 2020, daprodustat was first approved in Japan for the treatment of renal anemia. …
Chromium nicotinate
Approved
Experimental
Edetic acid
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
Approved
Vet approved
Matched Description: … A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. …
Ziprasidone
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Description: … life of patients and caregivers. ... treat manic episodes in bipolar disorder although the mechanism of action is unknown. ... several treatment options for psychotic disorders have been introduced to market since the realization of …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Medroxyprogesterone acetate
Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Categories: … Sex Hormones and Modulators of the Genital System …
Trazodone
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of ... [T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms ... reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Matched Categories: … Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome …
Upadacitinib
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage...
Approved
Investigational
Matched Description: … [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated ... [A189165] Despite a variety of therapeutic agents available for treatment, up to 40% of the patients ... (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of …
Vildagliptin
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... [L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia. ... [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- …
Rimegepant
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. ... subsequently approved by the European Commission in April 2022 for both the treatment and prevention of ... [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine …
Degarelix
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in...
Approved
Matched Description: … Degarelix is used for the treatment of advanced prostate cancer. ... Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … baricitinib for the treatment of COVID-19 in May 2022. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... Novel drugs that target orexin receptors gained increasing attention after discovering the role of orexin ... was designed via an intensive drug discovery program to improve the potency and maximize the duration of …
Tolcapone
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Approved
Withdrawn
Matched Description: … Tolcapone is associated with a risk of hepatotoxicity. ... It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. …
Loracarbef
Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Ciclopirox
Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective in treating Tinea versicolor.
Approved
Investigational
Matched Description: … , Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of …
Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
Approved
Matched Description: … Clinical trials suggest its efficacy in the treatment of partial seizures. ... derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of …
Rezafungin
Rezafungin is an echinocandin antifungal drug.[A258393,L45633] Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure. Rezafungin has a half-life higher than 130 hours and can be administered once a week...
Approved
Investigational
Matched Description: … Rezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily ... [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and ... L45633]
Clinical studies have shown that rezafungin is non-inferior to caspofungin for the treatment of …
Metreleptin
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia,...
Approved
Matched Description: … of adipose tissue. ... [L41315] Administration of metreleptin results in improvement of metabolic symptoms including improvements ... of leptin deficiency in people with lipodystrophy. …
Propiolactone
Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, …
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of...
Approved
Investigational
Matched Description: … Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate ... the growth of normal and malignant prostatic tissue. ... Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. …
Budesonide
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532]
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Description: … of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. ... Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions …
Ertugliflozin
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.
Approved
Investigational
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … RET RTK inhibitors for the treatment of RET-driven cancers. ... , [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of ... [A202049, A202055, L15986]
Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is …
Diflunisal
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Description: … Though its mechanism of action has not been clearly established, most of its actions appear to be associated ... with inhibition of prostaglandin synthesis via the arachidonic acid pathway. ... Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of …
Sincalide
Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Displaying drugs 326 - 350 of 8238 in total